Spencer S Stiles, Group President at Stryker SYK, executed a substantial insider sell on November 18, according to an SEC filing. Stryker shares are trading up 0.07% at $389.67 at the time of this ...

Stryker , a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

SOLASCURE Ltd ("SolasCure"), a biotechnology company developing a novel treatment to transform chronic wound care and the U.S. Army Institute of Surgical Research ("USAISR"), today announced a ...

We got some really interesting ideas on how to do that." Likewise, Stefan Stryker, CEO of Calidar, a startup that’s pioneering 4D mammography to improve the precision of breast cancer diagnoses, ...

Biotechnology is the exploitation of living systems or molecules from them for commercial gain. Although the word 'biotechnology' is only a few decades old, humankind has been using biotechnology for ...

Thousands of North Korean troops are massing in Kursk Oblast in western Russia. The U.S. Defense Department expects that, any day now, these troops will march to the front line in Kursk to help ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

Beware: ghosts of biotech’s past. Welcome to Fierce Biotech’s graveyard, a yearly ritual in which we remember the companies that shuttered operations in 2024. We don’t take these closures ...

Stryker remains a top-tier competitor in a number of attractive medical markets, including orthopedic implants, surgical instruments, endoscopy, and neurovascular devices. It enjoys a long record ...

Full-Year 2024 Adjusted EPS Guidance: $12 to $12.10. Stryker Corp (NYSE:SYK) reported robust organic sales growth of 11.5% in the third quarter, with strong performance across medsurg ...